Overactive Bladder (OAB)

Mirabegron Granted Priority Review for Neurogenic Detrusor Overactivity

Publish Date January 11, 2021

The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization.

Gemtesa Approved for Overactive Bladder Treatment

Publish Date January 4, 2021

The approval was based on data from the pivotal phase 3 EMPOWUR study.

Overactive Bladder Symptoms Often Remain After Surgery for Severe Prolapse

Publish Date December 16, 2020

In a study, approximately half of patients did not experience resolution of overactive bladder symptoms after anterior prolapse repair surgery.

Alpha Blockers May Not Improve Female Lower Urinary Tract Symptoms

Publish Date December 16, 2020

The role of alpha adrenergic blockers in the treatment of urinary dysfunction and associated symptoms in women remains unclear.

Study Identifies Predictors of OnabotulinumtoxinA Therapy Continuation

Publish Date December 15, 2020

In a study, only 39% of patients with overactive bladder continued BTX therapy for more than 5 years.

Urinary Symptom Severity Affects Adherence to Diuretic Treatment

Publish Date December 1, 2020

Adherence to diuretic therapy decreases as lower urinary tract symptoms increase in severity, according to a new study.

Anticholinergics Linked to Increased Dementia Risk

Publish Date November 30, 2020

Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.

Tooth Loss Associated With Overactive Bladder

Publish Date November 25, 2020

In a study, patients with chronic periodontitis and overactive bladder (OAB) had significantly fewer teeth (12.8 vs 21.5) compared with patients who did not have OAB.

Vibegron for Overactive Bladder Improves Quality of Life

Publish Date November 24, 2020

At 52 weeks, 71.1% of patients treated with vibegron experienced at least a 50% decline in total incontinence episodes from baseline.

Implantable Tibial Neurostimulator Promising for Urge Urinary Incontinence

Publish Date November 23, 2020

In a pilot study, the eCoin device yielded a dry rate of 30.33% at 36 weeks.